Misguided Pricing Tactics Delay Access To Medicines, Warns NHS England
Pharmaceutical companies must not delay patient access to medicine through “salami slicing” pricing strategies, says Blake Dark, commercial medicines director at NHS England.
You may also be interested in...
Speakers at a meeting in London examined the key provisions of the new voluntary pricing and access scheme, which replaced the PPRS at the beginning of January. The Pink Sheet spoke to the Association of the British Pharmaceutical Industry’s Paul Catchpole about enhanced planning for the introduction of new treatments on the national health service, and the shape of the new “commercial flexibilities” intended to allow earlier patient access to innovation.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.